in patients with inflammatory bowel disease
|
|
- Warren Hart
- 5 years ago
- Views:
Transcription
1 Aliment Pharmacol Ther 2005; 22: doi: /j x Incidence, risk factors and clinical course of thiopurine-induced liver injury in patients with inflammatory bowel disease G. BASTIDA, P. NOS, M. AGUAS, B. BELTRÁN, Á. RUBÍN, F. DASÍ & J. PONCE Gastroenterology Unit, La Fe Hospital, Valencia, Spain Accepted for publication 20 July 2005 SUMMARY Background: The incidence of thiopurine-induced hepatotoxicity in patients with inflammatory bowel disease varies in different studies. Aims: To assess the rate of thiopurine-induced liver toxicity in patients with inflammatory bowel disease; to determine the predictive factors and to characterize its clinical course and management. Methods: A cohort of 161 patients was prospectively followed for a median of 271 days. Hepatotoxicity was established when alanine transaminase or alkaline phosphatase plasma levels were greater than twice the upper normal limit. Results: Abnormal liver function was detected in 21 patients (13%; 95% CI: 7 18). Hepatotoxicity occurred in 16 patients (10%; 95% CI: 6 16) after a median of 85 days. In five cases, treatment was withdrawn due to hepatotoxicity. Use of corticosteroids was associated with hepatotoxicity (OR: 4.94; 95% CI: ) with antitumour necrosis factor concomitant therapy showing a protective role (OR: 0.3; 95% CI: ). c-glutamyl transferase plasma levels at the onset of hepatotoxicity showed the best predictive value for treatment withdrawal (area under the receiver operating characteristic curve: 0.95). Conclusions: The incidence of hepatotoxicity in inflammatory bowel disease patients receiving thiopurines is relevant, mainly in patients co-treated with corticosteroids. c-glutamyl transferase plasma level is a useful biomarker in therapy withdrawal prediction. INTRODUCTION Nowadays, thiopurines, azathioprine (AZA) and mercaptopurine (6-mercaptopurine; MP), are the most commonly used immunomodulatory drugs in patients with inflammatory bowel disease (IBD). 1 The occurrence of side-effects, however, is a major drawback in the use of AZA or MP and concerns regarding both short and long-term toxicity have restricted their use. 2 The side-effects of thiopurines can be divided into doseindependent or allergic/idiosincrasic and pharmacologically explainable dose-dependent events. The most Correspondence to: Dr G. Bastida, Gastroenterology Unit, La Fe Hospital, Campanar 21, Valencia, Spain. gbastidap@sepd.org frequently observed dose-independent events are rash, fever and artralgia, pancreatitis and hepatitis. 3, 4 The most important dose-related side-effect is myelosuppression. Hepatotoxicity may also be dose-dependent and can be reversible upon reduction of dose or discontinuation of treatment. Both acute hepatocelular hepatitis and colestatic hepatitis have been described during thiopurines treatment. 5 The incidence of hepatotoxicity was initially described as low; Present et al. 3 with 1800 patients-year of follow-up reported an incidence of drug hepatitis of 0.3%, despite this data, incidence varies among different series 6 8 and its real impact and management in clinical practice has not been fully characterized. Recently, a variation on incidence of hepatotoxicity among different diseases has been reported, 9 probably reflecting the influence of different genetic and acquired Ó 2005 Blackwell Publishing Ltd 775
2 776 G. BASTIDA et al. factors on individual susceptibility; the role of these acquired factors, as concomitant medications have been poorly documented. The aims of this study were first to assess the rate of hepatotoxicity in IBD patients under thiopurine treatment; secondly, to determine the potential predictive factors for the occurrence of hepatotoxicity and thirdly, to characterize its clinical course and management. PATIENTS AND METHODS population All patients starting treatment with AZA or MP since May 2000 were prospectively included. Diagnoses of IBD was established according to the criteria of Lennard-Jones. 10 In patients with Crohn s disease (CD), lesion location (ileum, colon, ileum and colon or upper gastrointestinal tract) and behaviour of disease (stricturing, penetrating or non-stricturing and non-penetrating) were classified in accordance with the Vienna criteria. 11 s with ulcerative colitis (UC) were classified in accordance with the extent of the disease. Demographic information, gender, age at diagnosis, concomitant medication, extraintestinal manifestations and indication of immunosuppressive therapy were obtained before starting on treatment. Thiopurine methyl transferase (TPMT) activity was recorded since May The AZA was introduced at 50 mg daily and increased gradually to doses of 2.5 mg/kg daily. 12 Those patients who had gastrointestinal intolerance to AZA were treated with MP initially at 0.5 mg/kg daily, increasing to 1.5 mg/kg daily. Subjects were seen in out-patient clinic at 2, 4 and 8 weeks and then every 3 months. Complete blood count and differential, alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (AP), c-glutamyl transferase (GGT), bilirubin, sedimentation rate, C-reactive protein, fibrinogen, albumin and iron were monitored at every visit. Amylase and lipase were not determined routinely. In each visit the patient was interrogated about any drug side-effect using a specific questionnaire. If treatment was discontinued, reasons were recorded. Outcome definitions Abnormal liver function tests (LFTs) were established when ALT or AP levels were >50% the upper normal limit. Hepatotoxicity was defined by ALT or AP levels greater than twice the upper normal limit in patients with previous normal values. 13 Lower elevations of LFTs were considered as mild elevations. To assess the causality we used the Council for International Organizations of Medical Sciences (CIOMS) criteria. 14 When abnormal LFTs was detected the patient was specifically interrogated about drugs or alcohol intake. All patients underwent an abdominal ultrasound, serological test to rule out hepatitis B and C infection and laboratory test including autoantibodies (antinuclear autoantibodies, antismooth muscle autoantibodies, antiliver/kidney autoantibodies and antimitochondrial autoantibodies), ceruloplasmin, iron metabolism and a-1-antitrypsin. Hepatotoxicity was classified in three groups using biochemical criteria based on serum activity of ALT and AP and their ratio: 14 (i) acute hepatocelular hepatitis defined by ALT above twice the upper normal limit or by a ratio ALT/AP >5; (ii) acute cholestatic hepatitis defined by an isolated increase of AP or by a ratio ALT/AP <2 and (iii) mixed pattern defined by an ALT/AP ratio between 2 and 5. When abnormal LFTs were detected the dose of thiopurines was reduced until LFTs normalization, and then the dosage of immunosuppressant was increased to the higher tolerated dose. If LFTs did not return to normal values with tapering of thiopurines, therapy was withdrawn. Statistics Results are expressed as median and range. Data were tested for normality distribution, the natural logarithms of variables were used to reduce the heterogeneity of variance if necessary. Categorical data are expressed as counts (%). Chi-square with continuity correction or Fisher s exact tests were used to assess differences between categorical variables. Independent samples Student s t-test was used to assess differences between continuous variables. A two-sided P-value of <0.05 was considered statistically significant. To identify independent predictors during out-patient follow-up, variables that achieved a P-value of <0.1 and those we considered clinically relevant were included in a multivariate analysis by using a logistic regression procedure analysis. Receiver operating characteristic curves (ROC) were generated by plotting sensitivity (y-axis) vs. 1 ) specificity (x-axis) or true-positive rates vs. false-positive rates.
3 HEPATOTOXICITY OF THIOPURINES IN INFLAMMATORY BOWEL DISEASE 777 RESULTS During the period of study 172 patients started on immunosuppressive treatment; 11 refused the participation in the study, thus a cohort of 161 patients were included and followed. characteristics, indications of treatment and concomitant medications are listed in Table 1, and baseline laboratory findings, TPMT activity and dose of thiopurines are listed in Table 2. Globally occurred 95 side-effects in 70 (44%) patients: 16 patients had two side-effects, three patients had three side-effects and one patient had four side-effects. The first side-effect occurred after a median time of 41 days (range: 1 951). Treatment was withdrawn in 46 (29%) patients after a median time of 58 days (range: ). The major reason for stopping the medication was the appearance of side-effects (32 patients, 20%). Eleven patients switch from AZA to MP because of gastrointestinal upset, symptoms recurred in five patients and thiopurine treatment was definitely removed. Other reasons for discontinuation of medication were that surgery become necessary in five (3%), the treatment was Table 1. Comparison of patient characteristics, indications of treatment and concomitant medications between patients with and without liver toxicity Variable No hepatotoxicity, n (%; n ¼ 145) Hepatotoxicity, n (%; n ¼ 16) P-value Age (years; range) 32 (14 72) 36 (23 53) N.S. Male 81 (56) 11 (69) N.S. Crohn s disease 116 (80) 13 (81.2) N.S. Azathioprine 145 (93) 16 (100) N.S. Disease site Ileum 32 (27.6) 3 (23.1) N.S. Ileum and colon 42 (36.2) Colon 34 (29.3) 8 (61.5) N.S. Upper gastrointestinal 8 (6.9) 2 (15.4) N.S. tract Pancolitis 13 (44.8) 1 (33.3) N.S. Extensive colitis 4 (13.8) 1 (33.3) N.S. Left-sided colitis 8 (27.6) 1 (33.3) N.S. Proctosigmoiditis 4 (13.8) N.S. Disease behaviour in patients with CD Penetrating 49 (42.2) 4 (30.7) N.S. Stricturing 26 (22.4) 2 (15.4) N.S. Inflammatory 41 (35.3) 7 (53.8) N.S. Extraintestinal manifestations Musculoskeletal 49 (33.8) 9 (56.3) N.S. Skin 5 (3.4) 1 (6.3) N.S. Ophthalmic 3 (2.1) N.S. Perianal disease 46 (30.5) 5 (31.2) N.S. Concomitant medication 5-Aminosalicylates 17 (11.7) 4 (25) N.S. Oral corticosteroids 85 (58.6) 14 (87.5) Antibiotics 36 (24.8) 3 (18.8) N.S. Ciclosporin 4 (2.8) N.S. Infliximab 22 (15.2) 1 (6.25) N.S. Topical therapy 24 (16.5) 3 (18.7) N.S. Indication for treatment Induction of remission 26 (17.9) 2 (12.5) N.S. Steroid dependence 58 (40) 11 (68.8) Prevention of recurrence 35 (24.1) 2 (12.5) N.S. Fistulizing disease 19 (13.1) N.S. Maintenance after severe attack 5 (3.4) N.S. Others 2 (1.4) 1 (6.3) N.S.
4 778 G. BASTIDA et al. No hepatotoxicity (n ¼ 145) Hepatotoxicity (n ¼ 16) P-value Leucocyte count ( 10 3 /ll) 9.35 ( ) 11.7 ( ) Neutrophil count ( 10 3 /ll) 6.0 ( ) 7.9 ( ) Haemoglobin (g/dl) 12.7 ( ) 14.3 ( ) Cell volume 86 (66 101) 89 (82 102) N.S. Platelet count ( 10 3 /ll) 314 ( ) 344 ( ) N.S. Sedimentation rate (mm/h) 18 (1 110) 15 (4 51) N.S. C-reactive protein (mg/dl) 8 (0 294) 6 (0 26) N.S. Fibrinogen (mg/dl) 371 ( ) 330 ( ) N.S. Albumin (g/l) 3.9 ( ) 4.1 (3.5 5) N.S. Aspartate aminotransferase (IU/L) 16 (5 101) 18 (5 30) N.S. Alanine aminotransferase (IU/L) 18 (1 102) 27 (17 57) N.S. Alkaline phosphatase (IU/L) 66 (16 324) 71 (25 96) N.S. c-glutamyl transferase (IU/L) 20 (8 254) 30 (18 207) N.S. Bilirubin (mg/dl) 0.4 ( ) 0.4 ( ) N.S. Iron (lg/dl) 45 (12 182) 67 (33 117) N.S. Potassium (mm) 4.2 ( ) 4.3 ( ) N.S. TPMT in (IU/mL) red blood cells 19.8 ( ) 21.8 ( ) N.S. Dose of AZA (mg/kg) 1.9 ( ) 2.1 ( ) N.S. Table 2. Comparison of baseline laboratory findings, thiopurine methyl transferase (TPMT) activity and dose of thiopurines between patients with and without liver toxicity considered to be ineffective in four cases (2.5%), the patients requested stopping the medication because the potential side-effects in four (2.5%) or the patient wished to become pregnant while off the therapy in one (0.6%) patient. HCV viral load of copies/ml with HCV genotype 1b and the liver biopsy revealed a histological activity index (HAI) of seven of 14 with and a fibrosis stage of two of four. In this patient the LFTs returned to normal values, continuing on full dose of AZA. Abnormal LFTs and hepatotoxicity Elevation of LFTs was detected in 21 (13%; 95% CI: 7 18) patients. Five (3%) patients (95% CI: 1 7) had a mild elevation of LFTs, none of them stopped the medication. Hepatotoxicity occurred in 16 (10%; 95% CI: 6 16) patients. demographics, baseline values of LFTs, TPMT activity and indications of treatment of all the patients with liver injury are listed in Table 3. Hepatotoxicity was detected after a median of 85 days (range: 2 951; Figure 1), an acute hepatocelular hepatitis in 14 cases and an acute cholestatic hepatitis in two. All patients were treated with AZA when hepatotoxicity occurred. In all cases abdominal ultrasound, antinuclear autoantibodies, antismooth muscle autoantibodies, antiliver/kidney autoantibodies, antimitochondrial autoantibodies, ceruloplasmin, iron metabolism, a-1- antitrypsin and serological markers of the hepatitis B virus (HBV) were normal. One patient had antihepatitis C virus (HCV) antibodies and was not considered to have hepatotoxicity. This patient was tested for viral RNA and underwent a liver biopsy. The patient had a Predictive factors for hepatotoxicity Univariate analyses revealed that concomitant treatment with systemic steroids, haemoglobin level, leucocyte and neutrophil count at the onset of treatment were significant predictive factors for the appearance of liver toxicity. Multivariate analyses revealed that only the use of corticosteroids at the onset of treatment was found to be a significant positive predictive factor for the appearance of hepatoxicity (OR: 4.94; 95% CI: ). Concomitant anti-tumour necrosis factor (TNF) therapy showed a protective effect (OR: 0.3; 95% CI: ) although with no statistical significance. Clinical course of liver injury, therapy withdrawal and predictive factors for treatment discontinuation Full details of the 16 patients with liver injury are listed in Table 4. Treatment was abandoned due to hepatotoxicity in five patients after a median of 51 days (range: 2 919): four cases with hepatocelular hepatitis and one with cholestatic hepatitis. In all patients
5 HEPATOTOXICITY OF THIOPURINES IN INFLAMMATORY BOWEL DISEASE 779 Table 3. characteristics, baseline values of liver function test and concomitant medication of patients with liver injury Age (years) Sex (M/F) F F M F M M M M M M F M M M F M CD/UC CD UC CD CD CD CD CD UC CD CD UC CD CD CD CD CD TPMT (IU/mL) red blood cells Baseline LFTs values ALT (IU/L; 0 40) AST (IU/L; 0 40) AP (IU/L; ) GGT (IU/L; 11 50) Bilirubin (mg/dl; ) Concomitant medication 5-Aminosalicylates No No No Yes Yes No No No No No Yes No Yes No No No Oral corticosteroids Yes Yes Yes Yes Yes Yes No Yes Yes Yes Yes Yes Yes Yes No Yes Antibiotics No No No No No No No No No Yes No Yes Yes No No No Infliximab No No No No No No No No Yes No No No No No No No Azathioprine (AZA)/mercaptopurine AZA AZA AZA AZA AZA AZA AZA AZA AZA AZA AZA AZA AZA AZA AZA AZA ALT, alanine transaminase; AST, aspartate transaminase; AP, alkaline phosphatase; GGT, c-glutamyl transferase; M, male; F, female; CD, Crohn s disease; UC, ulcerative colitis; TPMT, thiopurine methyl transferase. s still at risk abnormal LFTs normalized after treatment was discontinued. In two of these five patients in whom the treatment was withdrawn, rechallenge was attempted with lower doses of AZA with recurrence of elevated LFTs within 2 weeks. In the remaining 11 patients, seven were able to tolerate full doses of thiopurines without further elevations of LFTs and in four patients the treatment should be withdrawn because of other causes different from liver toxicity during the follow-up before they reached the full doses of thiopurines. Among the patients with liver injury, those patients in whom the treatment was withdrawn due to hepatotoxicity showed higher levels of AST, ALT, AP, GGT and total bilirubin at the onset of hepatotoxicity, although with non-statistical significance. Plasma levels of GGT at the onset of liver toxicity, had, in the multivariate analysis, the best predictive value for treatment withdrawal with an area under the ROC curve of 0.95 (95% CI: ). The best positive and negative predictive values were achieved in this model using a cut-off level of four times the upper normal limit: sensitivity of 1.0, specificity of 0.87, predictive value of a positive test of 0.57, predictive value of a negative test of 1.0, likelihood ratio of a positive test of 0.76 and likelihood ratio of a negative test of 0. DISCUSSION Time (days) Figure 1. Cumulative risks (%) of hepatotoxicity in 161 patients under thiopurinic immunomodulators under surveillance. To our knowledge, this is the first prospective epidemiological study that specifically addresses the incidence of
6 780 G. BASTIDA et al. Table 4. Time, dose of azathioprine, laboratory findings at the onset and outcome of liver injury Time in days until liver injury Dose of AZA when toxicity (mg/kg) LFTs values at the onset of liver injury ALT (IU/L; 0 40) AST (IU/L; 0 40) AP (IU/L; ) GGT (IU/L; 11 50) Bilirubin (mg/dl; ) Treatment withdrawal Due to hepatotoxicity No No No No Yes No No Yes Yes No No No No Yes No Yes During follow-up due to other causes Yes Yes No Yes No No No Yes No No No Resolution of liver test anormalities Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Able to tolerate full doses of AZA No No Yes No Yes Yes Yes No Yes Yes Yes Rechallenge No No No No No No No No Yes No No No No No No Yes Relapse after rechallenge Yes Yes ALT, alanine transaminase; AST, aspartate transaminase; AP, alkaline phosphatase; GGT, c-glutamyl transferase. hepatotoxicity in IBD patients treated with thiopurinic immunomodulators. The incidence of abnormal LFTs or liver toxicity is a relevant finding during the follow-up of patients treated with thiopurinic immunomodulators as we showed in this study conducted with a cohort of 161 IBD patients. There is a lack of recent published series that specifically assess thiopurine-induced hepatotoxocity, but some recent studies with IBD patients do not describe any case of liver injury during the follow-up. 15, 16 This is important because systematic biochemical analysis is not performed routinely in recent studies that analyse the side-effects of thiopurinic immunomodulators. 17 Thus, the first clinical application that derives directly from our study is that LFTs monitoring is mandatory in these patients and should be performed for the duration of therapy as it has been proposed previously. 18 Probably the main limitation of studies evaluating drug-induced liver toxicity is related with diagnosis, due to the absence of specific markers or tests. Therefore, the diagnosis relied entirely on circumstantial evidence and only in the cases of relapse after rechallenge we had the certainty that AZA or MP were the offending drug. 19 Liver biopsy is an invasive procedure with significant morbidity and was not performed routinely to all patient presented with abnormal LFTs. Although liver biopsy is not required to establish the diagnosis of drug-induced liver toxicity, 19 it is impossible to know in our study whether there was a correlation between histological damage and elevated enzymes. Based on the absence of histological confirmation and in the fact that an important percentage of patients were able to tolerate full-dose therapy, we cannot assert that we are handling with a true hepatotoxicity which implies hepatocyte damage rather than a form of tolerance. It is important to remark that we ruled out other causes that might have explained the liver injury as well as alcohol or hepatotoxic drugs intake, but we should be aware that the patient could be hiding the consumption of illegal drugs or herbal remedies. 20 It is worth noting some considerations related to the clinical course of thiopurine-induced liver injury. At first it is important to point out that a small percentage of patients, <5%, presented with a slight elevation of LFTs that did not have clinical implications: the abnormalities in liver chemical tests returned to normal values during the follow-up and was not necessary to adjust dose of immunomodulator. As with other drugs, 21 thiopurineinduced liver injury occurred more frequently within the
7 HEPATOTOXICITY OF THIOPURINES IN INFLAMMATORY BOWEL DISEASE 781 first months of treatment, 50% of cases within the first 3 months. Moreover, treatment withdrawal because of hepatotoxicity occurred in most of cases, 75%, during this period of time. Despite this, in some cases the liver injury was only detected after a long period of follow-up leading to therapy withdrawal. This finding is surprising because the long delay makes the role of the suspected drug unlikely; the explanation of this event could be related to a cumulative effect of the metabolites on liver, 22 or to the confluence of multiple factors that could be triggers of an autoimmune liver injury. We found acute hepatocelular hepatitis in 87.5% of patients, in contrast with previous descriptions that considered pure cholestasis as the typical pattern. 23 In all cases LFTs returned to normal values and no chronic disease was detected. When hepatotoxicity occurred, the treatment was withdrawn in 31% of patients, but an important percentage, 44%, was able to continue on full dose of thiopurine once the dose was temporarily adjusted. This group of patients had a dose-dependent hepatotoxicity rather than an immunoallergic hepatitis. The rationale about how these patients were able to return to full doses of thiopurinic immunomodulators may be theoretically explained by the confluence of multiple factors in the onset of hepatotoxicity: dose of immunomodulator, concomitant treatment, quality of nutrition, drug interaction, etc. If we consider the high percentage of patients able to continue with proper doses of AZA or MP after temporal adjustment of the dose, it would be of particular usefulness to predict those patients prone to tolerate immunomodulators. We noted that the values of LFTs when toxicity is detected (first determination) were higher in the patients in whom the treatment was finally withdrawn, and the plasma levels of GGT had the best sensibility and specificity to discriminate those patients in whom the treatment was removed. This is an additional important observation and could be very useful in clinical practice because many patients could continue on immunomodulator treatment and thus, maximize the clinical effectiveness of thiopurines, cornerstone of maintenance treatment in IBD. One important limitation of this study is the number of patients only 16 used to calculate the sensitivity and specificity, so we should be cautious when analysing the conclusions; this approach should be tested prospectively in a larger series to corroborate our findings. Previous reports have shown an increase risk of hepatotoxicity in men, 23 in the present study men had higher risk of liver injury as well, although this difference did not reach statistical significance. Now it is well recognized the role of TNF as a key mediator in hepatototoxicity 24 and could explain the protective effect observed in our study in those patients with anti-tnf (infliximab) concomitant therapy. One interesting finding of our study is that the use of steroids was associated with an increased risk to develop liver injury. Animal studies suggest that AZA effects correlate to oxidative stress, mitochondrial dysfunction and activation of stress-activated protein kinase pathways leading to necrotic cell death Thus, steroids may precipitate hepatotoxicity by exacerbating insulin resistance, recognized as a proinflammatory condition with increased oxidative stress and activation of cellular signalling pathways, 28 or by exacerbating risk factors for fatty liver as central obesity, diabetes or hypertriglyceridaemia, which predisposes to oxidative stress by amplifying the capacity for free radical chain reactions. 29 In vitro studies 25, 27 support the role of intracellular reduced glutathione (GSH) depletion in AZA-induced hepatocyte injury and the protective role of N-acetyl-l-cysteine (NAC), however, these findings must be completed. 27 Based on these considerations, the use of NAC or other antioxidants could represent a novel strategy for: hepatotoxicity prevention, mainly in those receiving AZA and steroids concomitantly. In conclusion, this study provides an approach to the real incidence of thiopurine-related hepatotoxicty in IBD patients in clinical practice setting. We have identified the corticosteroids usage at the onset of treatment as a positive predictive factor to hepatotoxicity and, we have proposed the use of GGT plasma levels to monitor liver toxicity clinical course, in order to optimize effectiveness of thiopurinic immunomodulators. ACKNOWLEDGEMENTS This study was supported in part by a grant from the Instituto de Salud Carlos III (C03/03). Guillermo Bastida MD was supported by a grant from the Fundacion para la investigacion Hospital Universitario La Fe. The authors would like to thank Dr Carlos Cara (UCB Pharma, Spain) for his help in writing the manuscript. REFERENCES 1 Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002; 347:
8 782 G. BASTIDA et al. 2 Markowitz J, Grancher K, Kohn N, Daum F. Immunomodulatory therapy for pediatric inflammatory bowel disease: changing patterns of use, Am J Gastroenterol 2002; 97: Present DH, Meltzer SJ, Krumholz MP, Wolke A, Korelitz BI. 6- Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med 1989; 111: Marion JF. Toxicity of 6-mercaptopurine/azathioprine in patients with inflammatory bowel disease. Inflamm Bowel Dis 1998; 4: de Jong DJ, Derijks LJ, Naber AH, Hooymans PM, Mulder CJ. Safety of thiopurines in the treatment of inflammatory bowel disease. Scand J Gastroenterol 2003; 239 (Suppl.): Cuffari C, Theoret Y, Latour S, Seidman G. 6-Mercaptopurine metabolism in Crohn s disease: correlation with efficacy and toxicity. Gut 1996; 39: George J, Present DH, Pou R, Bodian C, Rubin PH. The longterm outcome of ulcerative colitis treated with 6- mercaptopurine. Am J Gastroenterol 1996; 91: Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 2002; 50: Weersma RK, Peters FT, Oostenbrug LE, et al. Increased incidence of azathioprine-induced pancreatitis in Crohn s disease compared with other diseases. Aliment Pharmacol Ther 2004; 20: Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol 1989; 24 (Suppl. 170): Gasche C, Scholmerich J, Brynskov J, et al. A simple classification of Crohn s disease: report of the working party for the World Congresses of Gastroenterology, Vienna Inflamm Bowel Dis 2000; 6: Lichtenstein GR. Use of laboratory testing to guide 6- mercaptopurine/azathioprine therapy. Gastroenterology 2004; 127: Benichou C. Criteria of drug-induced liver disorders. Report an international consensus meeting. J Hepatol 1990; 11: Lucena MI, Camargo R, Andrade RJ, Perez-Sanchez CJ, Sanchez De La Cuesta F. Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology 2001; 33: Ansari A, Hassan C, Duley J, et al. Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease. Aliment Pharmacol Ther 2002; 16: Goldstein ES, Marion JF, Present DH. 6-Mercaptopurine is effective in Crohn s disease without concomitant steroids. Inflamm Bowel Dis 2004; 10: de Jong DJ, Goullet M, Naber TH. Side effects of azathioprine in patients with Crohn s disease. Eur J Gastroenterol Hepatol 2004; 16: Nielsen OH, Vainer B, Rask-Madsen J. Review article: The treatment of inflammatory bowel disease with 6- mercaptopurine or azathioprine. Aliment Pharmacol Ther 2001; 15: Larrey D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Semin Liver Dis 2002; 22: Kong SC, Hurlstone DP, Pocock CY, et al. The incidence of selfprescribed oral complementary and alternative medicine use by patients with gastrointestinal diseases. J Clin Gastroenterol 2005; 39: Lee WM. Drug-induced hepatotoxicity. N Engl J Med 2003; 349: Kaplowitz N. Biochemical and cellular mechanisms of toxic liver injury. Semin Liver Dis 2002; 22: Larrey D. Drug-induced liver diseases. J Hepatol 2000; 32 (Suppl. 1): Liu ZX, Kaplowitz N. Immune-mediated drug-induced liver disease. Clin Liver Dis 2002; 6: Lee AU, Farrell GC. Mechanism of azathioprine-induced injury to hepatocytes: roles of glutathione depletion and mitochondrial injury. J Hepatol 2001; 35: Menor C, Fernandez-Moreno MD, Fueyo JA, et al. Azathioprine acts upon rat hepatocyte mitochondria and stress-activated protein kinases leading to necrosis: protective role of N-acetyl-L-cysteine. J Pharmacol Exp Ther 2004; 311: Tapner MJ, Jones BE, Wu WM, Farrell GC. Toxicity of low dose azathioprine and 6-mercaptopurine in rat hepatocytes. Roles of xanthine oxidase and mitochondrial injury. J Hepatol 2004; 40: Choudhury J, Sanyal AJ. Insulin resistance and the pathogenesis of nonalcoholic fatty liver disease. Clin Liver Dis 2004; 8: Farrell GC. Drugs and steatohepatitis. Semin Liver Dis 2002; 22:
Azathioprine for Induction and Maintenance of Remission in Crohn s Disease
Azathioprine for Induction and Maintenance of Remission in Crohn s Disease William J. Sandborn, MD Chief, Division of Gastroenterology Director, UCSD IBD Center Objectives Azathioprine as induction and
More informationMEDICAL POLICY. Proprietary Information of YourCare Health Plan
MEDICAL POLICY Clinical criteria used to make utilization review decisions are based on credible scientific evidence published in peer reviewed medical literature generally recognized by the medical community.
More informationPositioning Biologics in Ulcerative Colitis
Positioning Biologics in Ulcerative Colitis Bruce E. Sands, MD, MS Acting Chief, Gastrointestinal Unit Massachusetts General Hospital Associate Professor of Medicine Harvard Medical School Sequential Therapies
More informationIBD Understanding Your Medications. Thomas V. Aguirre, MD Santa Barbara GI Consultants
IBD Understanding Your Medications Thomas V. Aguirre, MD Santa Barbara GI Consultants IBD Understanding Your Medications (& Your Doctor) Thomas V. Aguirre, MD Santa Barbara GI Consultants Disclosure I
More informationClinical Use and Practical Application of TPMT Enzyme and 6-Mercaptopurine Metabolite Monitoring in IBD Ernest G. Seidman, MD
GENETIC TESTING FOR IBD Clinical Use and Practical Application of TPMT Enzyme and 6-Mercaptopurine Metabolite Monitoring in IBD Ernest G. Seidman, MD Division of Gastroenterology, Hepatology, and Nutrition,
More informationPosition of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy
Position of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy Stephen B. Hanauer, MD University of Chicago Potential Conflicts: Centocor/Schering, Abbott, UCB, Elan, Berlex, PDL Goals of Treatment
More informationDENOMINATOR: All patients aged 18 and older with a diagnosis of inflammatory bowel disease
Measure #270: Inflammatory Bowel Disease (IBD): Preventive Care: Corticosteroid Sparing Therapy National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY
More informationMEDICAL POLICY SUBJECT: GENOTYPING OR PHENOTYPING FOR THIOPURINE METHYLTRANSFERASE (TPMT) FOR PATIENTS TREATED WITH AZATHIOPRINE (6-MP)
MEDICAL POLICY SUBJECT: GENOTYPING OR PHENOTYPING PAGE: 1 OF: 5 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product (including
More informationCrohn's Disease. The What, When, and Why of Treatment
Crohn's Disease The What, When, and Why of Treatment Brian Feagan, MD, FACG Professor of Medicine and Epidemiology and Biostatistics Director, Robarts Clinical Trials Robarts Research Institute University
More informationEfficacy and Safety of Treatment for Pediatric IBD
Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Associate Professor of Clinical Pediatrics Division of Gastroenterology,
More informationSerologic Markers CONVENTIONAL ANTIBODIES ANTIBODIES UNCONVENTIONAL. AIH Type I
Autoimmune Hepatitis By Thomas Frazier Objective What we need to know about AIH Diagnosis Treatment Difficulties in both Liver transplantation concerns AASLD Guidelines: Hepatology. 2010 Jun;51(6):2193-213.
More informationInitiation of Maintenance Treatment in Moderate to Severe New Onset Crohn s Disease
Initiation of Maintenance Treatment in Moderate to Severe New Onset Crohn s Disease The Case for Starting with Anti-TNFα Agents Maria Oliva-Hemker, M.D. Chief, Division of Pediatric Gastroenterology &
More informationCLINICAL TRIAL PROTOCOL
CLINICAL TRIAL PROTOCOL Azathioprine maintenance therapy in steroid-refractory Ulcerative Colitis responsive to i.v. Cyclosporine A: Is a therapeutic bridge with oral Cyclosporine A necessary? Miquel A.
More informationAutoimmune Hepatobiliary Diseases PROF. DR. SABEHA ALBAYATI CABM,FRCP
Autoimmune Hepatobiliary Diseases PROF. DR. SABEHA ALBAYATI CABM,FRCP Autoimmune hepatobiliary diseases The liver is an important target for immunemediated injury. Three disease phenotypes are recognized:
More informationCommon Questions in Crohn s Disease Therapy. Case
Common Questions in Crohn s Disease Therapy Jean-Paul Achkar, MD, FACG Kenneth Rainin Chair for IBD Research Cleveland Clinic Case 23 yo male with 1 year history of diarrhea, abdominal pain and 15 pound
More informationThe Best of IBD at UEGW (Crohn s)
The Best of IBD at UEGW (Crohn s) Iyad Issa MD Head of Gastroenterology, Rafik Hariri Univ Hosp Adjunct Faculty, School of Medicine, Leb Univ Founding Faculty, School Of Medicine, Leb Am Univ 1 The Best
More informationFistulizing Crohn s Disease: The Aggressive Approach
Fistulizing Crohn s Disease: The Aggressive Approach Bruce E. Sands, MD, MS MGH Crohn s and Colitis Center and Gastrointestinal Unit Massachusetts General Hospital Boston, USA Case Presentation: Summary
More informationLIVER SPECIALTY CONFERENCE USCAP Maha Guindi, M.D. Clinical Professor of Pathology Cedars-Sinai Medical Center Los Angeles, CA
LIVER SPECIALTY CONFERENCE USCAP 2016 Maha Guindi, M.D. Clinical Professor of Pathology Cedars-Sinai Medical Center Los Angeles, CA Nothing to disclose Case History 47-year-old male, long standing ileal
More informationClinical Course of Infliximab Treatment in Korean Pediatric Ulcerative Colitis Patients: A Single Center Experience
pissn: 2234-8646 eissn: 2234-8840 http://dx.doi.org/10.5223/pghn.2014.17.1.31 Pediatric Gastroenterology, Hepatology & Nutrition 2014 March 17(1):31-36 Original Article PGHN Clinical Course of Infliximab
More informationResponse to First Intravenous Steroid Therapy Determines the Subsequent Risk of Colectomy in Ulcerative Colitis Patients
Response to First Intravenous Steroid Therapy Determines the Subsequent Risk of Colectomy in Ulcerative Colitis Patients Tamás Molnár 1, Klaudia Farkas 1, Tibor Nyári 2, Zoltán Szepes 1, Ferenc Nagy 1,
More informationLatest Treatment Updates for Ulcerative Colitis: Evolving Treatment Goals
Latest Treatment Updates for Ulcerative Colitis: Evolving Treatment Goals Stephen Hanauer, MD Professor of Medicine Medical Director, Digestive Disease Center Northwestern Medicine Chicago, Illinois Speaker
More informationPredicting the natural history of IBD. Séverine Vermeire, MD, PhD Department of Gastroenterology University Hospital Leuven Belgium
Predicting the natural history of IBD Séverine Vermeire, MD, PhD Department of Gastroenterology University Hospital Leuven Belgium Patient 1 Patient 2 Age 22 Frequent cramps and diarrhea for 6 months Weight
More informationMono or Combination Therapy with. Individualized Approach
Mono Combination Therapy with Biologics i in IBD: Developing an Individualized Approach David T. Rubin, MD, FACG Co-Direct, Inflammaty Bowel Disease Center Fellowship Program Direct University of Chicago
More informationTreatment of Inflammatory Bowel Disease. Michael Weiss MD, FACG
Treatment of Inflammatory Bowel Disease Michael Weiss MD, FACG What is IBD? IBD is an immune-mediated chronic intestinal disorder, characterized by chronic or relapsing inflammation within the GI tract.
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 20 October 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 20 October 2010 MEZAVANT LP 1200 mg, prolonged-release gastro-resistant tablets B/60 (CIP code: 378 689-2) Applicant
More informationDrug Induced Liver Injury (DILI)
Drug Induced Liver Injury (DILI) Aisling Considine- Consultant Hepatology Pharmacist. King s College Hospital NHS Foundation Trust aislingconsidine@nhs.net Drug Induced Liver Injury /Disease Acute Liver
More informationModerately to severely active ulcerative colitis
Adalimumab in the Treatment of Moderate-to-Severe Ulcerative Colitis: ULTRA 2 Trial Results Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients
More information8 Larissa International Congress of Internal Medicine
8 Larissa International Congress of Internal Medicine Larissa, 18 th March 2016 IBD & Viral Hepatitis Alessio Aghemo, MD, PhD Division of Gastroenterology and Hepatology Fondazione IRCCS Ca Granda Ospedale
More informationIndications for use of Infliximab
Indications for use of Infliximab Moscow, June 10 th 2006 Prof. Dr. Dr. Gerhard Rogler Klinik und Poliklinik für Innere Medizin I Universität Regensburg Case report 1989: Diagnosis of Crohn s disease of
More informationFat, ballooning, plasma cells and a +ANA. Yikes! USCAP 2016 Evening Specialty Conference Cynthia Guy
Fat, ballooning, plasma cells and a +ANA. Yikes! USCAP 2016 Evening Specialty Conference Cynthia Guy Goals Share an interesting case Important because it highlights a common problem that we re likely to
More informationSeptember 12, 2015 Millie D. Long MD, MPH, FACG
Update on Biologic Therapy in 2015 September 12, 2015 Millie D. Long MD, MPH, FACG Assistant Professor of Medicine Inflammatory Bowel Disease Center University of North Carolina-Chapel Hill Outline Crohn
More informationOptimizing Immunomodulators and
Optimizing Immunomodulators and Biologics i in Inflammatory Bowel Disease Sunanda Kane, MD, MSPH, FACG Professor of Medicine Division of Gastroenterology and Hepatology Mayo Clinic Rochester, Minnesota,
More informationBeyond Anti TNFs: positioning of other biologics for Crohn s disease. Christina Ha, MD Cedars Sinai Inflammatory Bowel Disease Center
Beyond Anti TNFs: positioning of other biologics for Crohn s disease Christina Ha, MD Cedars Sinai Inflammatory Bowel Disease Center Objectives: To define high and low risk patient and disease features
More informationEfficacy and Safety of Treatment for Pediatric IBD
Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Assistant Professor of Clinical Pediatrics Division of Gastroenterology,
More informationSupplementary Table 1. The distribution of IFNL rs and rs and Hardy-Weinberg equilibrium Genotype Observed Expected X 2 P-value* CHC
Supplementary Table 1. The distribution of IFNL rs12979860 and rs8099917 and Hardy-Weinberg equilibrium Genotype Observed Expected X 2 P-value* CHC rs12979860 (n=3129) CC 1127 1145.8 CT 1533 1495.3 TT
More informationManagement of autoimmune hepatitis. Pierre-Emmanuel RAUTOU Inserm U970, Paris Service d hépatologie, Hôpital Beaujon, Clichy, France
Management of autoimmune hepatitis Pierre-Emmanuel RAUTOU Inserm U970, PARCC@HEGP, Paris Service d hépatologie, Hôpital Beaujon, Clichy, France Case 1 52 year-old woman, referred for liver blood tests
More informationSafety and Efficacy of Endoscopic Dilatation of Strictures in Crohn s Disease
Safety and Efficacy of Endoscopic Dilatation of Strictures in Crohn s Disease Vinna An, Ashwinna Asairinachan, Michael Johnston, James Keck, Paul Salama, Steven Brown, Rodney Woods Department of Colorectal
More informationALT and aspartate aminotransferase (AST) levels were measured using the α-ketoglutarate reaction (Roche,
Supplemental Methods Analytical determinations ALT and aspartate aminotransferase (AST) levels were measured using the α-ketoglutarate reaction (Roche, Basel, Switzerland). Glucose, triglyceride, total
More informationManagement of autoimmune hepatitis. Pierre-Emmanuel RAUTOU Inserm U970, Paris Service d hépatologie, Hôpital Beaujon, Clichy, France
Management of autoimmune hepatitis Pierre-Emmanuel RAUTOU Inserm U970, PARCC@HEGP, Paris Service d hépatologie, Hôpital Beaujon, Clichy, France 41 year-old woman, coming to emergency department for fatigue
More informationMercaptopurine and inflammatory bowel disease: the other thiopurine
30-008/207/09//0-6 Revista Española de Enfermedades Digestivas Copyright 207. SEPD y ARÁN EDICIONES, S.L. Rev Esp Enferm Dig 207, Vol. 09, N.º, pp. 0-6 ORIGINAL PAPERS Mercaptopurine and inflammatory bowel
More informationDefinitions. Clinical remission: Resolution of symptoms (stool frequency 3/day, no bleeding and no urgency)
CROHN S DISEASE Definitions Clinical remission: Resolution of symptoms (stool frequency 3/day, no bleeding and no urgency) Recurrence: The reappearance of lesions after surgical resection Endoscopic remission:
More informationClinical guideline Published: 10 October 2012 nice.org.uk/guidance/cg152
Crohn's disease: management Clinical guideline Published: 10 October 2012 nice.org.uk/guidance/cg152 NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationAAIM: GI Workshop Follow Up to Case Studies. Non-alcoholic Fatty Liver Disease Ulcerative Colitis Crohn s Disease
AAIM: GI Workshop Follow Up to Case Studies Non-alcoholic Fatty Liver Disease Ulcerative Colitis Crohn s Disease Daniel Zimmerman, MD VP and Medical Director, RGA Global October 2015 Non-alcoholic Fatty
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 3 October 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 3 October 2012 REMICADE 100 mg, powder for concentrate for solution for infusion B/1 vial (CIP code: 562 070-1) Applicant:
More informationInternational IBD Genetics Consortium
International IBD Genetics Consortium PRED4 Thiopurine Induced Pancreatitis Case Report Form Please stick study label here On completion, please return to: Claire Bewshea IBD Pharmacogenetics Research
More informationAnne Griffiths MD, FRCPC. SickKids Hospital, University of Toronto. Buenos Aires, August 16, 2014
Management and Medical Therapies for Crohn disease: strategies to enhance mucosal healing Anne Griffiths MD, FRCPC SickKids Hospital, University of Toronto Buenos Aires, August 16, 2014 New onset Crohn
More informationThe role of ARFI and APRI in diagnosis of liver fibrosis on patients with common chronic liver diseases
RESEARCH ARTICLE The role of ARFI and APRI in diagnosis of liver fibrosis on patients with common chronic liver diseases Objective: This study aimed to investigate the value of liver fibrosis assessment
More informationIncidence of Neoplasms in Patients Who Develop Sustained Leukopenia During or After Treatment With 6-Mercaptopurine for Inflammatory Bowel Disease
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2006;4:1025 1029 Incidence of Neoplasms in Patients Who Develop Sustained Leukopenia During or After Treatment With 6-Mercaptopurine for Inflammatory Bowel Disease
More informationPediatric PSC A children s tale
Pediatric PSC A children s tale September 8 th PSC Partners seeking a cure Tamir Miloh Assistant Professor Pediatric Hepatology Mount Sinai Hospital, NY Incidence Primary Sclerosing Cholangitis (PSC) ;
More informationACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries
ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries Ashwani K. Singal, MD, MS, FACG 1, Ramon Bataller, MD, PhD, FACG 2, Joseph Ahn, MD, MS, FACG (GRADE Methodologist) 3, Patrick S. Kamath,
More informationMedical Therapy for Pediatric IBD: Efficacy and Safety
Medical Therapy for Pediatric IBD: Efficacy and Safety Betsy Maxwell, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition Pediatric IBD: Defining Remission
More informationAccepted Article. Mercaptopurine and inflammatory bowel disease: the other thiopurine
Accepted Article Mercaptopurine and inflammatory bowel disease: the other thiopurine Fernando Bermejo San José, Alicia Algaba, Sergio López Durán, Iván Guerra, Marta Aicart, María Hernández-Tejero, Elena
More informationPEDIATRIC INFLAMMATORY BOWEL DISEASE
PEDIATRIC INFLAMMATORY BOWEL DISEASE Alexis Rodriguez, MD Pediatric Gastroenterology Advocate Children s Hospital Disclosers Abbott Nutrition - Speaker Inflammatory Bowel Disease Chronic inflammatory disease
More informationABNORMAL LIVER FUNCTION TESTS. Dr Uthayanan Chelvaratnam Hepatology Consultant North Bristol NHS Trust
ABNORMAL LIVER FUNCTION TESTS Dr Uthayanan Chelvaratnam Hepatology Consultant North Bristol NHS Trust INTRODUCTION Liver function tests Cases Non invasive fibrosis measurement Questions UK MORTALITY RATE
More informationOPTIMAL USE OF IMMUNOMODULATORS AND BIOLOGICS Edward V. Loftus, Jr., MD, FACG
1C: Advances in Inflammatory Bowel Disease OPTIMAL USE OF IMMUNOMODULATORS AND BIOLOGICS Edward V. Loftus, Jr., MD, FACG narrow interpretation of this presentation topic would A be a discussion of dosing
More informationPersonalized Medicine in IBD: Where Are We in 2013
Personalized Medicine in IBD: Where Are We in 2013 David A. Schwartz, MD Director, Inflammatory Bowel Disease Center Associate Professor of Medicine Vanderbilt University Medical Center What is Personalized
More informationTreatment Goals. Current Therapeutic Pyramids Crohn s Disease Ulcerative Colitis 11/14/10
Current Management of IBD: From Conventional Agents to Biologics Stephen B. Hanauer, M.D. University of Chicago Treatment Goals Induce and maintain response/ remission Prevent complications Improve quality
More informationNatural History of Chronic Hepatitis B
Natural History of Chronic Hepatitis B Anna SF Lok, MD Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research University of Michigan Ann Arbor,
More informationAspartate aminotransferase-to-platelet ratio index in children with cholestatic liver diseases to assess liver fibrosis
The Turkish Journal of Pediatrics 2015; 57: 492-497 Original Aspartate aminotransferase-to-platelet ratio index in children with cholestatic liver diseases to assess liver fibrosis Aysel Ünlüsoy-Aksu 1,
More informationAutoimmune Hepatitis. What Drug and for How Long? Hepatology Day May 30 th, 2015
Autoimmune Hepatitis What Drug and for How Long? Rajaa Chatila, MD Associate Professor of Medicine Director, Internal Medicine Residency Program Lebanese American University Hepatology Day May 30 th, 2015
More informationCrohn's Disease. The What, When, and Why of Treatment
Crohn's Disease The What, When, and Why of Treatment Sunanda Kane, MD, FACG Professor of Medicine Department of Gastroenterology and Hepatology Mayo Clinic Rochester, MN In my lecture today, I will be
More informationEffect of Adalimumab on an Enterocutaneous Fistula in Patients with Crohn s Disease: A Case Series
CASE REPORT Effect of Adalimumab on an Enterocutaneous Fistula in Patients with Crohn s Disease: A Case Series Kaori Fujiwara, Takuya Inoue, Naoki Yorifuji, Munetaka Iguchi, Taisuke Sakanaka, Ken Narabayashi,
More informationTreatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort
Alimentary Pharmacology and Therapeutics Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort N. Gies, K. I. Kroeker, K. Wong & R. N. Fedorak Division
More informationA Rational Evidence-based Approach to Abnormal Liver Tests
A Rational Evidence-based Approach to Abnormal Liver Tests Jane D. Ricaforte-Campos, MD FPCP, FPSG, FPSDE 2013 HSP Post-graduate Course Radisson Blu Hotel, Cebu City misnomer Liver Function Tests Does
More informationImproving outcome of Inflammatory Bowel Disease in children
Improving outcome of Inflammatory Bowel Disease in children Dinesh Pashankar, MD Pediatric Gastroenterologist Director- Pediatric IBD program Yale University School of Medicine Pediatric Gastroenterology
More informationAli Keshavarzian MD Rush University Medical Center
Treatment: Step Up or Top Down? Ali Keshavarzian MD Rush University Medical Center Questions What medication should IBD be treated with? Can we predict which patients with IBD are high risk? Is starting
More informationNEW CONCEPTS IN CROHN S DISEASE GLENDON BURRESS, MD PEDIATRIC GASTROENTEROLOGY ROCKFORD, IL
NEW CONCEPTS IN CROHN S DISEASE GLENDON BURRESS, MD PEDIATRIC GASTROENTEROLOGY ROCKFORD, IL CROHN S DISEASE Chronic disease of uncertain etiology Etiology- genetic, environmental, and infectious Transmural
More informationHigh-dose azathioprine in children with inflammatory bowel disease
Aliment Pharmacol Ther 2003; 17: 913 921. doi: 10.1046/j.0269-2813.2003.01540.x High-dose azathioprine in children with inflammatory bowel disease D. FUENTES*, F. TORRENTE*, S. KEADY*, K. THIRRUPATHY*,
More informationMucosal healing: does it really matter?
Oxford Inflammatory Bowel Disease MasterClass Mucosal healing: does it really matter? Professor Jean-Frédéric Colombel, New York, USA Oxford Inflammatory Bowel Disease MasterClass Mucosal healing: does
More informationPBC features and management in the era of UDCA and Budesonide
PBC features and management in the era of UDCA and Budesonide Raoul Poupon, MD Université P&M Curie, AP-Hôpitaux de Paris, Inserm, Paris, France The changing pattern of PBC Over the last 2 decades: More
More informationAutoimmune Hepatitis in Clinical Practice
1 Autoimmune Hepatitis in Clinical Practice Atif Zaman, MD MPH Professor of Medicine Senior Associate Dean for Clinical and Faculty Affairs School of Medicine Oregon Health & Science University Disclosure
More informationT he treatment strategy for Crohn s disease (CD) is
237 INFLAMMATORY BOWEL DISEASE Impact of the increasing use of immunosuppressants in Crohn s disease on the need for intestinal surgery J Cosnes, I Nion-Larmurier, L Beaugerie, P Afchain, E Tiret, J-P
More informationOutcomes of immunosuppressors and biologic drugs in inflammatory bowel diseases: a real life experience
Outcomes of immunosuppressors and biologic drugs in inflammatory bowel Treatments and therapeutic approaches in IBD are constantly evolving. The newly emerged biologic treatments are one such evolving
More informationAzathioprine treatment in inflammatory bowel disease patients: type and time of onset of side effects
European Review for Medical and Pharmacological Sciences Azathioprine treatment in inflammatory bowel disease patients: type and time of onset of side effects 2014; 18: 165-170 E.V. AVALLONE 1, R. PICA
More informationSpeaker Introduction
Speaker Introduction Stephen B. Hanauer, MD Professor of Medicine and Clinical Pharmacology University of Chicago Pritzker School of Medicine Chief of Gastroenterology, Hepatology, and Nutrition University
More informationTransient elastography in chronic liver diseases of other etiologies
4 Post Meeting A.I.S.F. Unmet Clinical Needs in Hepatology: New and upcoming diagnostic tools" Transient elastography in chronic liver diseases of other etiologies Dr. Vincenza Calvaruso Gastroenterologia
More informationMild-moderate Ulcerative Colitis Sequential & Combined treatments need to be tested. Philippe Marteau, Paris, France
Mild-moderate Ulcerative Colitis Sequential & Combined treatments need to be tested Philippe Marteau, Paris, France Sequential vs combined treatments When should one switch? Sequential vs combined treatments
More information5/2/2018 SHOULD DEEP REMISSION BE A TREATMENT GOAL? YES! Disclosures: R. Balfour Sartor, MD
5/2/218 SHOULD DEEP REMISSION BE A TREATMENT GOAL? YES! Disclosures: R. Balfour Sartor, MD Grant support for preclinical studies: Janssen, Gusto Global, Vedanta, Artizan BALFOUR SARTOR, MD DISTINGUISHED
More informationEfficacy of 6-mercaptopurine treatment after azathioprine hypersensitivity in inflammatory bowel disease
Online Submissions: wjg.wjgnet.com World J Gastroenterol 2008 July 21; 14(27): 4342-4346 wjg@wjgnet.com World Journal of Gastroenterology ISSN 1007-9327 doi:10.3748/wjg.14.4342 2008 The WJG Press. All
More informationDisease behavior in adult patients- are there predictors for stricture or fistula formation?
Disease behavior in adult patients- are there predictors for stricture or fistula formation? Falk Symposium 168, Madrid, Spain Iris Dotan, M.D., Head, IBD Center, Department of Gastroenterology and Liver
More informationJohn F. Valentine, MD Inflammatory Bowel Disease Program University of Utah
John F. Valentine, MD Inflammatory Bowel Disease Program University of Utah Hawaii 1/20/2017 DISCLOSURES Research Support: NIH, Pfizer, Celgene, AbbVie, Roche/Genentech, Takeda, CCFA OBJECTIVES Review
More informationAutoimmune Hepatitis. Dr. Stefania Casu Hepatology, UVCM, Inselspital Bern. November 14th, 2018
Autoimmune Hepatitis Dr. Stefania Casu Hepatology, UVCM, Inselspital Bern November 14th, 2018 AIH - Definition Manns MP J Hepatol 2015, vol 62, P 100-111 AIH - Definition Autoimmune hepatitis (AIH) is
More informationLong-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance
Long-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance Gi-Ae Kim, Han Chu Lee *, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim,
More informationInflammatory Bowel Disease: Clinical updates. Dr Jeff Chao Princess Alexandra Hospital
Inflammatory Bowel Disease: Clinical updates Dr Jeff Chao Princess Alexandra Hospital Inflammatory bowel disease 2017 Clinical updates and future directions Pathogenesis Treatment targets Therapeutic agents
More informationCrohn s Disease: Should We Treat Based on Symptoms or Based on Objective Markers of Inflammation?
Crohn s Disease: Should We Treat Based on Symptoms or Based on Objective Markers of Inflammation? Edward V. Loftus, Jr., M.D. Professor of Medicine Division of Gastroenterology and Hepatology Mayo Clinic
More informationChoosing and Positioning Biologic Therapy for Crohn s Disease: (Still) Looking for the Crystal Ball
Choosing and Positioning Biologic Therapy for Crohn s Disease: (Still) Looking for the Crystal Ball Siddharth Singh, MD, MS Assistant Professor of Medicine Division of Gastroenterology Division of Biomedical
More informationHHS Public Access Author manuscript Hepatology. Author manuscript; available in PMC 2017 March 01.
Febuxostat-Induced Acute Liver Injury Matt Bohm, DO, Raj Vuppalanchi, MD, Naga Chalasani, MD, and Drug Induced Liver Injury Network (DILIN) Department of Medicine, Indiana University School of Medicine,
More informationSuspected Isoflurane Induced Hepatitis from Cross Sensitivity in a Post Transplant for Fulminant Hepatitis from Halothane.
ISPUB.COM The Internet Journal of Anesthesiology Volume 25 Number 1 Suspected Isoflurane Induced Hepatitis from Cross Sensitivity in a Post Transplant for Fulminant Hepatitis from Halothane. V Sampathi,
More informationPerianal and Fistulizing Crohn s Disease: Tough Management Decisions. Jean-Paul Achkar, M.D. Kenneth Rainin Chair for IBD Research Cleveland Clinic
Perianal and Fistulizing Crohn s Disease: Tough Management Decisions Jean-Paul Achkar, M.D. Kenneth Rainin Chair for IBD Research Cleveland Clinic Talk Overview Background Assessment and Classification
More informationReview article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease
Aliment Pharmacol Ther 23; 18 (Suppl. 2): 1 5. Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease P. MUNKHOLM Department of Medical Gastroenterology, Hvidovre
More informationAnti-tumour necrosis factor treatment of inflammatory bowel disease in liver transplant recipients
Alimentary Pharmacology and Therapeutics Anti-tumour necrosis factor treatment of inflammatory bowel disease in liver transplant recipients A. B. Mohabbat*, W. J. Sandborn, E. V. Loftus Jr, R. H. Wiesner
More informationLaurie S. Conklin, M.D. Inflammatory Bowel Disease Program Children s National Medical Center
Laurie S. Conklin, M.D. Inflammatory Bowel Disease Program Children s National Medical Center CROHN S DISEASE Patchy inflammation Mouth to anus involvement Full-thickness inflammation Variable involvement
More informationPatient selection for azathioprine - typical courses of Crohn s disease
Patient selection for azathioprine - typical courses of Crohn s disease remitting 44% steroid refractory 20% remitting 48% steroid refractory 21% 36% steroid dependent 31% steroid dependent Munkholm et
More informationCIRROSI E IPERTENSIONE PORTALE NELLA DONNA
Cagliari, 16 settembre 2017 CIRROSI E IPERTENSIONE PORTALE NELLA DONNA Vincenza Calvaruso, MD, PhD Ricercatore di Gastroenterologia Gastroenterologia & Epatologia, Di.Bi.M.I.S. Università degli Studi di
More informationIBD 101. Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition
IBD 101 Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition Objectives Identify factors involved in the development of inflammatory bowel
More informationIn 1993, the International Autoimmune Hepatitis Group
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2012;10:417 421 Validation and Modification of Simplified Diagnostic Criteria for Autoimmune Hepatitis in Children ELIZABETH MILETI,* PHILIP ROSENTHAL,*, and MARION
More informationI have no disclosures relevant to this presentation LIVER TESTS: WHAT IS INCLUDED? LIVER TESTS: HOW TO UTILIZE THEM OBJECTIVES
LIVER TESTS: HOW TO UTILIZE THEM I have no disclosures relevant to this presentation José Franco, MD Professor of Medicine, Surgery and Pediatrics Medical College of Wisconsin OBJECTIVES Differentiate
More informationXiao-Ling Chi, Mei-Jie Shi, Huan-Ming Xiao, Yu-Bao Xie, and Gao-Shu Cai. Correspondence should be addressed to Xiao-Ling Chi;
Evidence-Based Complementary and Alternative Medicine Volume 2016, Article ID 3743427, 6 pages http://dx.doi.org/10.1155/2016/3743427 Research Article The Score Model Containing Chinese Medicine Syndrome
More informationTacrolimus therapy as an alternativ Titlemaintaining remission in patients w colitis. Author(s) Yamamoto, Shuji; Nakase, Hiroshi; M Masuda, Satohiro; Inui, Ken-ichi; C Citation Journal of clinical gastroenterolog
More informationDiagnostic evaluation of suspected Drug-Induced Liver Injury
Diagnostic evaluation of suspected Drug-Induced Liver Injury Ynto de Boer, MD Department of Gastroenterology and Hepatology Disclosure No disclosures Drug-induced liver injury? Outline What is DILI? What,
More information